Form 4: Immunocore R&D Head Exercises, Sells Shares

Immunocore's Head of R&D, David M. Berman, executed stock options and subsequently sold the acquired shares for a profit, as per a pre-arranged 10b5-1 trading plan.

Summary

• David M. Berman, Head of R&D at Immunocore Holdings plc, reported transactions involving the company's ordinary shares.
• On September 30, 2025, Berman exercised 61,849 employee share options at an exercise price of $17.46 per share.
• Concurrently, Berman sold 61,849 ordinary shares at a weighted average price of $35.23 per share.
• The sales occurred in multiple transactions with prices ranging from $35.01 to $35.48.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Berman on May 9, 2025.
• Following these transactions, Berman beneficially owns 136,790 derivative securities (employee share options) and 0 ordinary shares from this specific transaction set.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction executed under a pre-arranged 10b5-1 plan, which is a common practice for executives managing their equity compensation. It does not reflect new operational or financial news for the company.

Positives

• The executive realized a significant profit from the exercise of options and subsequent sale, indicating a personal financial gain.
• The transaction was executed under a Rule 10b5-1 trading plan, which demonstrates pre-planning and adherence to insider trading regulations, reducing concerns about opportunistic trading.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be interpreted by some investors as a lack of conviction in the company's near-term stock price appreciation, although this is a routine personal financial management event.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction filing (Form 4) for an executive at a publicly traded biotechnology company. Such transactions, especially when executed under a 10b5-1 plan, are common for executives managing their personal finances and equity compensation.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance, providing an affirmative defense against insider trading allegations by pre-arranging transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-arranged plan and is unlikely to have a significant direct impact on shareholders, beyond the general market perception of executive share sales.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Immunocore Holdings plc, IMCR, Form 4, Insider Transaction, Stock Options, 10b5-1 Plan, Executive Compensation, Share Sale, David M. Berman